-
Symposium highlights supplements, menopause, and other trending topics in nutrition
Nutrition experts, including Kevin Klatt, PhD, RD, and Hillary Wright, MEd, RDN, LDN, analyzed several diet-related considerations that could have downstream implications for an individual’s diabetes management.
-
Debate weighs whether BMI should remain central to obesity diagnosis
Francesco Rubino, MD, spoke in favor of moving beyond body mass index in diagnosing obesity. Leigh Perreault, MD, defended the long-time cornerstone of obesity diagnosis.
-
Panelists present pros and cons of full, immediate integration of AI into healthcare delivery
Nestoras Mathioudakis, MD, MHS, and Neda Laiteerapong, MD, discussed the pros and cons—from alleviating burnout to passing off hallucinations—of bringing artificial intelligence fully on board in clinical care today.
-
Emerging technology, new clinical algorithm target DKA
During multiple sessions at the 2026 Scientific Sessions, experts, including Viral N. Shah, MD, explored the potential, challenges, and questions surrounding continuous ketone monitoring and other considerations for diabetic ketoacidosis, which results in more than 250,000 hospital admissions in the U.S. each year.
-
Outstanding Scientific Achievement Award lecturer highlights evolution of unimolecular therapies
Timo D. Müller, PhD, shared his insights on hormonal control of metabolism by glucose-dependent insulinotropic polypeptide (GIP) and next-generation incretin-based polyagonists during a session recognizing his contributions to diabetes and metabolic research.
-
Oral small-molecule GLP-1 RA improves blood glucose and weight reduction
The VISTA and SOLSTICE phase 2b trials evaluated the use of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron in adults. Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, and Vanita R. Aroda, MD, shared the latest study data.
-
ACHIEVE results show A1C reduction, weight loss in type 2 diabetes
Investigators aim to use orforglipron to address the limitations of injectable GLP-1 RAs. The primary goal is to provide an alternative that meets health needs without the logistical challenges of current treatments, said Rodolfo J. Galindo, MD.
-
Outstanding Educator in Diabetes Award recipient: Value the stories behind the numbers
In her award lecture, Diana Isaacs, PharmD, BCACP, CDCES, BC-ADM, FADCES, FCCP, advocated embracing new tools and technology while keeping the people living with diabetes central to new approaches to care.
-
GLP-1 RA use, technology, unique needs of individuals are recurring themes in the latest updates to the Standards of Care in Diabetes
Six panelists, including Elizabeth Ann Beverly, PhD, explained the latest additions and changes within selected chapters to the Standards of Care in Diabetes—2026, the gold standard in evidence-based guidelines for diagnosing and managing diabetes and prediabetes.
-
Experts share the latest updates on the Standards of Care in Overweight and Obesity
The growing document provides evidence-based, unified guidance and actionable recommendations. Leigh Perreault, MD, presented a new chapter on screening diagnosis. Louis J. Aronne, MD, FACP, shared a new chapter on obesity medications.